Click for best price
Postmenopausal Vaginal Atrophy Drugs Market Size, Share 2022
Market Analysis and Insights: Global Postmenopausal Vaginal Atrophy Drugs Market
The global Postmenopausal Vaginal Atrophy Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Postmenopausal Vaginal Atrophy Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Postmenopausal Vaginal Atrophy Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Postmenopausal Vaginal Atrophy Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Postmenopausal Vaginal Atrophy Drugs market.
Global Postmenopausal Vaginal Atrophy Drugs Scope and Market Size
Postmenopausal Vaginal Atrophy Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Postmenopausal Vaginal Atrophy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Postmenopausal Vaginal Atrophy Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Segment by Application
- Offline Stores
- Online Stores
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- Taiwan
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- U.A.E
By Company
- Actavis plc
- Bionovo, Inc.
- Endoceutics, Inc.
- Novo Nordisk A/S
- Pfizer Inc.
- Teva Pharmaceuticals Ltd.
- Therapeutics MD, Inc.
- Shionogi & Company
- Allergan plc
- Shionogi & Co. Ltd.
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Postmenopausal Vaginal Atrophy Drugs product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Postmenopausal Vaginal Atrophy Drugs, with price, sales, revenue, and global market share of Postmenopausal Vaginal Atrophy Drugs from 2019 to 2022.
Chapter 3, the Postmenopausal Vaginal Atrophy Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Postmenopausal Vaginal Atrophy Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Postmenopausal Vaginal Atrophy Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Postmenopausal Vaginal Atrophy Drugs.
Chapter 13, 14, and 15, to describe Postmenopausal Vaginal Atrophy Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Postmenopausal Vaginal Atrophy Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global and United States Postmenopausal Vaginal Atrophy Drugs Market Report & Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
109 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 Postmenopausal Vaginal Atrophy Drugs Product Introduction
1.2 Global Postmenopausal Vaginal Atrophy Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales in Volume for the Year 2017-2028
1.3 United States Postmenopausal Vaginal Atrophy Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Postmenopausal Vaginal Atrophy Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Postmenopausal Vaginal Atrophy Drugs Sales in Volume for the Year 2017-2028
1.4 Postmenopausal Vaginal Atrophy Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Postmenopausal Vaginal Atrophy Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Postmenopausal Vaginal Atrophy Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Postmenopausal Vaginal Atrophy Drugs Market Dynamics
1.5.1 Postmenopausal Vaginal Atrophy Drugs Industry Trends
1.5.2 Postmenopausal Vaginal Atrophy Drugs Market Drivers
1.5.3 Postmenopausal Vaginal Atrophy Drugs Market Challenges
1.5.4 Postmenopausal Vaginal Atrophy Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Postmenopausal Vaginal Atrophy Drugs Market Segment by Type
2.1.1 Vaginal Gels
2.1.2 Creams
2.1.3 Tablets
2.1.4 Rings
2.1.5 Patches
2.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Type
2.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Postmenopausal Vaginal Atrophy Drugs Market Size by Type
2.3.1 United States Postmenopausal Vaginal Atrophy Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Postmenopausal Vaginal Atrophy Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Postmenopausal Vaginal Atrophy Drugs Market Segment by Application
3.1.1 Offline Stores
3.1.2 Online Stores
3.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Application
3.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Postmenopausal Vaginal Atrophy Drugs Market Size by Application
3.3.1 United States Postmenopausal Vaginal Atrophy Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Postmenopausal Vaginal Atrophy Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Postmenopausal Vaginal Atrophy Drugs Competitor Landscape by Company
4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Company
4.1.1 Top Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Postmenopausal Vaginal Atrophy Drugs Price by Manufacturer (2017-2022)
4.2 Global Postmenopausal Vaginal Atrophy Drugs Concentration Ratio (CR)
4.2.1 Postmenopausal Vaginal Atrophy Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Postmenopausal Vaginal Atrophy Drugs in 2021
4.2.3 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Postmenopausal Vaginal Atrophy Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Postmenopausal Vaginal Atrophy Drugs Market Size by Company
4.5.1 Top Postmenopausal Vaginal Atrophy Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Postmenopausal Vaginal Atrophy Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Postmenopausal Vaginal Atrophy Drugs Sales by Players (2020, 2021 & 2022)
5 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region
5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Postmenopausal Vaginal Atrophy Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Postmenopausal Vaginal Atrophy Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Actavis plc
7.1.1 Actavis plc Corporation Information
7.1.2 Actavis plc Description and Business Overview
7.1.3 Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
7.1.5 Actavis plc Recent Development
7.2 Bionovo, Inc.
7.2.1 Bionovo, Inc. Corporation Information
7.2.2 Bionovo, Inc. Description and Business Overview
7.2.3 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
7.2.5 Bionovo, Inc. Recent Development
7.3 Endoceutics, Inc.
7.3.1 Endoceutics, Inc. Corporation Information
7.3.2 Endoceutics, Inc. Description and Business Overview
7.3.3 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
7.3.5 Endoceutics, Inc. Recent Development
7.4 Novo Nordisk A/S
7.4.1 Novo Nordisk A/S Corporation Information
7.4.2 Novo Nordisk A/S Description and Business Overview
7.4.3 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Products Offered
7.4.5 Novo Nordisk A/S Recent Development
7.5 Pfizer Inc.
7.5.1 Pfizer Inc. Corporation Information
7.5.2 Pfizer Inc. Description and Business Overview
7.5.3 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
7.5.5 Pfizer Inc. Recent Development
7.6 Teva Pharmaceuticals Ltd.
7.6.1 Teva Pharmaceuticals Ltd. Corporation Information
7.6.2 Teva Pharmaceuticals Ltd. Description and Business Overview
7.6.3 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
7.6.5 Teva Pharmaceuticals Ltd. Recent Development
7.7 Therapeutics MD, Inc.
7.7.1 Therapeutics MD, Inc. Corporation Information
7.7.2 Therapeutics MD, Inc. Description and Business Overview
7.7.3 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
7.7.5 Therapeutics MD, Inc. Recent Development
7.8 Shionogi & Company
7.8.1 Shionogi & Company Corporation Information
7.8.2 Shionogi & Company Description and Business Overview
7.8.3 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Products Offered
7.8.5 Shionogi & Company Recent Development
7.9 Allergan plc
7.9.1 Allergan plc Corporation Information
7.9.2 Allergan plc Description and Business Overview
7.9.3 Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Products Offered
7.9.5 Allergan plc Recent Development
7.10 Shionogi & Co. Ltd.
7.10.1 Shionogi & Co. Ltd. Corporation Information
7.10.2 Shionogi & Co. Ltd. Description and Business Overview
7.10.3 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
7.10.5 Shionogi & Co. Ltd. Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Postmenopausal Vaginal Atrophy Drugs Industry Chain Analysis
8.2 Postmenopausal Vaginal Atrophy Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Postmenopausal Vaginal Atrophy Drugs Distributors
8.3 Postmenopausal Vaginal Atrophy Drugs Production Mode & Process
8.4 Postmenopausal Vaginal Atrophy Drugs Sales and Marketing
8.4.1 Postmenopausal Vaginal Atrophy Drugs Sales Channels
8.4.2 Postmenopausal Vaginal Atrophy Drugs Distributors
8.5 Postmenopausal Vaginal Atrophy Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Postmenopausal Vaginal Atrophy Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Postmenopausal Vaginal Atrophy Drugs Market Trends
Table 3. Postmenopausal Vaginal Atrophy Drugs Market Drivers
Table 4. Postmenopausal Vaginal Atrophy Drugs Market Challenges
Table 5. Postmenopausal Vaginal Atrophy Drugs Market Restraints
Table 6. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Postmenopausal Vaginal Atrophy Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Postmenopausal Vaginal Atrophy Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Postmenopausal Vaginal Atrophy Drugs Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturer, 2017-2022
Table 13. Global Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturer, (K Units), 2017-2022
Table 14. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturer, 2017-2022
Table 15. Global Postmenopausal Vaginal Atrophy Drugs Price by Manufacturer (2017-2022) & (USD/Unit)
Table 16. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Postmenopausal Vaginal Atrophy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2021)
Table 18. Top Players of Postmenopausal Vaginal Atrophy Drugs in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
Table 20. Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Postmenopausal Vaginal Atrophy Drugs Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Postmenopausal Vaginal Atrophy Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Postmenopausal Vaginal Atrophy Drugs Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Postmenopausal Vaginal Atrophy Drugs Sales by Players, (K Units), 2020, 2021 & 2022
Table 26. United States Postmenopausal Vaginal Atrophy Drugs Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Region (2017-2022) & (K Units)
Table 29. Global Postmenopausal Vaginal Atrophy Drugs Sales in Volume Forecast by Region (2023-2028) & (K Units)
Table 30. Global Postmenopausal Vaginal Atrophy Drugs Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Postmenopausal Vaginal Atrophy Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 33. North America Postmenopausal Vaginal Atrophy Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Region (2017-2028) & (K Units)
Table 35. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 37. Europe Postmenopausal Vaginal Atrophy Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 39. Latin Americaa Postmenopausal Vaginal Atrophy Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Country (2017-2028) & (K Units)
Table 41. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Actavis plc Corporation Information
Table 43. Actavis plc Description and Business Overview
Table 44. Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 45. Actavis plc Postmenopausal Vaginal Atrophy Drugs Product
Table 46. Actavis plc Recent Development
Table 47. Bionovo, Inc. Corporation Information
Table 48. Bionovo, Inc. Description and Business Overview
Table 49. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 50. Bionovo, Inc. Product
Table 51. Bionovo, Inc. Recent Development
Table 52. Endoceutics, Inc. Corporation Information
Table 53. Endoceutics, Inc. Description and Business Overview
Table 54. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 55. Endoceutics, Inc. Product
Table 56. Endoceutics, Inc. Recent Development
Table 57. Novo Nordisk A/S Corporation Information
Table 58. Novo Nordisk A/S Description and Business Overview
Table 59. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 60. Novo Nordisk A/S Product
Table 61. Novo Nordisk A/S Recent Development
Table 62. Pfizer Inc. Corporation Information
Table 63. Pfizer Inc. Description and Business Overview
Table 64. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 65. Pfizer Inc. Product
Table 66. Pfizer Inc. Recent Development
Table 67. Teva Pharmaceuticals Ltd. Corporation Information
Table 68. Teva Pharmaceuticals Ltd. Description and Business Overview
Table 69. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 70. Teva Pharmaceuticals Ltd. Product
Table 71. Teva Pharmaceuticals Ltd. Recent Development
Table 72. Therapeutics MD, Inc. Corporation Information
Table 73. Therapeutics MD, Inc. Description and Business Overview
Table 74. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 75. Therapeutics MD, Inc. Product
Table 76. Therapeutics MD, Inc. Recent Development
Table 77. Shionogi & Company Corporation Information
Table 78. Shionogi & Company Description and Business Overview
Table 79. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 80. Shionogi & Company Product
Table 81. Shionogi & Company Recent Development
Table 82. Allergan plc Corporation Information
Table 83. Allergan plc Description and Business Overview
Table 84. Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 85. Allergan plc Product
Table 86. Allergan plc Recent Development
Table 87. Shionogi & Co. Ltd. Corporation Information
Table 88. Shionogi & Co. Ltd. Description and Business Overview
Table 89. Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 90. Shionogi & Co. Ltd. Product
Table 91. Shionogi & Co. Ltd. Recent Development
Table 92. Key Raw Materials Lists
Table 93. Raw Materials Key Suppliers Lists
Table 94. Postmenopausal Vaginal Atrophy Drugs Customers List
Table 95. Postmenopausal Vaginal Atrophy Drugs Distributors List
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Postmenopausal Vaginal Atrophy Drugs Product Picture
Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Postmenopausal Vaginal Atrophy Drugs Market Size 2017-2028 (US$ Million)
Figure 4. Global Postmenopausal Vaginal Atrophy Drugs Sales 2017-2028 (K Units)
Figure 5. United States Postmenopausal Vaginal Atrophy Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Postmenopausal Vaginal Atrophy Drugs Market Size 2017-2028 (US$ Million)
Figure 7. United States Postmenopausal Vaginal Atrophy Drugs Sales 2017-2028 (K Units)
Figure 8. United States Postmenopausal Vaginal Atrophy Drugs Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Postmenopausal Vaginal Atrophy Drugs Market Share in Global, in Volume (K Units) 2017-2028
Figure 10. Postmenopausal Vaginal Atrophy Drugs Report Years Considered
Figure 11. Product Picture of Vaginal Gels
Figure 12. Product Picture of Creams
Figure 13. Product Picture of Tablets
Figure 14. Product Picture of Rings
Figure 15. Product Picture of Patches
Figure 16. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2022 & 2028
Figure 17. Global Postmenopausal Vaginal Atrophy Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 18. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type (2017-2028)
Figure 19. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2017-2028) & (K Units)
Figure 20. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 21. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2017-2028) & (USD/Unit)
Figure 22. United States Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2022 & 2028
Figure 23. United States Postmenopausal Vaginal Atrophy Drugs Sales in Value by Type (2017-2028) & (US$ Million)
Figure 24. United States Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type (2017-2028)
Figure 25. United States Postmenopausal Vaginal Atrophy Drugs Sales by Type (2017-2028) & (K Units)
Figure 26. United States Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type (2017-2028)
Figure 27. United States Postmenopausal Vaginal Atrophy Drugs Price by Type (2017-2028) & (USD/Unit)
Figure 28. Product Picture of Offline Stores
Figure 29. Product Picture of Online Stores
Figure 30. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2022 & 2028
Figure 31. Global Postmenopausal Vaginal Atrophy Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 32. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application (2017-2028)
Figure 33. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2017-2028) & (K Units)
Figure 34. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 35. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2017-2028) & (USD/Unit)
Figure 36. United States Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2022 & 2028
Figure 37. United States Postmenopausal Vaginal Atrophy Drugs Sales in Value by Application (2017-2028) & (US$ Million)
Figure 38. United States Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application (2017-2028)
Figure 39. United States Postmenopausal Vaginal Atrophy Drugs Sales by Application (2017-2028) & (K Units)
Figure 40. United States Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application (2017-2028)
Figure 41. United States Postmenopausal Vaginal Atrophy Drugs Price by Application (2017-2028) & (USD/Unit)
Figure 42. North America Postmenopausal Vaginal Atrophy Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 43. North America Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 44. U.S. Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 45. Canada Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 46. Europe Postmenopausal Vaginal Atrophy Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 47. Europe Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 48. Germany Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. France Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. U.K. Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. Italy Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 52. Russia Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 54. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 55. China Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. Japan Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. South Korea Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. India Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Australia Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. Taiwan Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Indonesia Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Thailand Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Malaysia Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 64. Philippines Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 65. Latin America Postmenopausal Vaginal Atrophy Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 66. Latin America Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 67. Mexico Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 68. Brazil Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 69. Argentina Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 70. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 71. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 72. Turkey Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 73. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 74. U.A.E Postmenopausal Vaginal Atrophy Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 75. Postmenopausal Vaginal Atrophy Drugs Value Chain
Figure 76. Postmenopausal Vaginal Atrophy Drugs Production Process
Figure 77. Channels of Distribution
Figure 78. Distributors Profiles
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed
